Business Context and Reporting Period
Company: Cardo Medical, Inc. (Note: Input metadata referenced "Biocardia," but the filing text identifies the registrant as Cardo Medical, Inc.)
Filing Type: Form 10-K
Period: Fiscal year ended December 31, 2010
Business Overview: An orthopedic medical device company specializing in reconstructive joint devices (knee, hip) and spinal surgical devices. The company operates two divisions: Reconstructive and Spine.
Strategic Shift: In October 2010, due to insufficient working capital and inability to secure financing, management decided to sell substantially all assets of both divisions. Consequently, operations are classified as "discontinued operations" for the 2010 reporting period.
Key Financial Metrics
| Metric | 2010 (Discontinued Ops) | 2009 (Discontinued Ops) |
|---|---|---|
| Net Sales | $3,312,000 | $1,869,000 |
| Gross Profit | $988,000 | $1,489,000 |
| Gross Margin | 29.8% | 79.7% |
| Operating Loss | $(11,536,000) | $(5,102,000) |
| Net Loss | $(11,509,000) | $(5,078,000) |
| Cash Used in Operating Activities | $(4,277,000) | $(4,783,000) |
| Cash Balance (Year End) | $127,000 | $4,973,000 |
| Total Assets Held for Sale | $4,765,000 | $8,837,000 |
Debt and Liquidity: As of December 31, 2010, total liabilities were $2,156,000, including $500,000 in related-party notes. Cash reserves were critically low at $127,000. Subsequent to year-end, the company secured a $972,000 promissory note from Arthrex, Inc. to fund working capital and pay off prior debts.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 77.2% to $3.3 million, driven by a 235.6% increase in Spine Division sales and a 43.4% increase in Reconstructive Division sales.
- Margin Compression: Gross margin collapsed from 79.7% in 2009 to 29.8% in 2010. This was primarily due to a $1.62 million non-cash inventory reserve for excess and obsolete inventory.
- Impairment Charges: The company recorded a $5.283 million non-cash impairment charge in 2010 related to goodwill and intangible assets, compared to zero in 2009. This charge wiped out the remaining value of goodwill and intangibles.
- Cost Reduction: Following the October 2010 decision to sell assets, the company terminated over half of its employees, reduced office space, and scaled back R&D expenses by 14.4%.
Outlook, Risks, and Unusual Items
Asset Sale Transactions
- Reconstructive Division: On January 24, 2011, Cardo entered an Asset Purchase Agreement with Arthrex, Inc. to sell Reconstructive Division assets for approximately $9.9 million cash plus the value of inventory/equipment (estimated at $4.7 million). The deal includes a 5% royalty on future net sales for 20 years. Closing is expected in Q2 2011.
- Spine Division: Negotiations are ongoing to sell Spine Division assets, with an anticipated closing in Q2 2011.
Going Concern
The independent auditors have issued a "going concern" opinion. The company has a history of losses, negative cash flows, and an accumulated deficit of $22.7 million. Continued operations are dependent on the successful closing of the asset sales or securing additional financing.
Risks and Contingencies
- Transaction Risk: Failure to close the asset sales could force the company to cease operations immediately due to insufficient working capital.
- Financing Risk: The company relies on a secured promissory note from Arthrex (up to $1.25 million) to bridge the gap until closing. Default on this note could result in foreclosure on all assets.
- Regulatory: Subject to FDA regulations and potential impacts from the 2010 Affordable Care Act, including a 2.3% excise tax on medical devices starting in 2013.
Investor Verification Checklist
- Closing Status: Verify if the Asset Purchase Agreement with Arthrex, Inc. has closed and if the Spine Division sale is proceeding as planned.
- Valuation of Assets: Confirm the final valuation of inventory and property, plant, and equipment included in the Arthrex transaction, as this impacts the total consideration received.
- Debt Obligations: Review the terms of the Arthrex Note and ensure no events of default have occurred regarding the $972,000 borrowed.
- Post-Sale Structure: Determine the company's plan post-asset sale, including the name change to "Tiger X Medical, Inc." and the strategy for utilizing royalty income or acquiring new assets.
- Inventory Reserve: Assess the accuracy of the $1.62 million inventory reserve taken in 2010 and whether it impacts the final sale price negotiations.